Major Partners: GVK Bio, India; International Centre for Diarrhoeal Disease Research, Bangladesh; Shaheed Suhrawardy Medical College and Hospital, Bangladesh; Community Based Medical College, Bangladesh.

Objective: To identify safe and effective shortcourse combination therapies using the existing drugs, miltefosine, paromomycin, and liposomal amphotericin B (AmBisome®), to provide simplified treatment options to facilitate control programmes. A two-step Phase III trial (initially in hospital followed by treatment in primary healthcare centres) using the same combinations as in the trial conducted by DNDi in India (see Implementation) was initiated in Bangladesh in mid-2010.